Promise already turning into fact: management shows the thing it told investors was coming is now measurably arriving, a
The model's full reasoning — Q3 2021 call → NOWe need to determine if management points to a growth-bearing development that it had previously told investors to expect, and demonstrates with real current-period activity that it is now arriving at or beyond pace, while conveying it's still early. Let's analyze the transcript. Key topics: vadadustat approval, launch preparation, Auryxia revenue growth, etc. Management discusses vadadustat's potential approval and launch. They mention "we are deep in commercial preparedness activities" and "we are preparing for a successful launch." They talk about the market opportunity, distribution with Vifor, TDAPA, etc. They also mention Auryxia revenue growth. But the question is about a growth-bearing development that management had previously told investors to expect, and now demonstrates with real current-period activity that it's arriving, while still early. Look for explicit references to prior expectations. For example, "As we said last quarter" or "consistent with what we laid out." There is mention of "we have been planning to be second of three" and now "we're planning to be first of two." That's a change in expectation, not a confirmation of prior expectation. They talk about Auryxia revenue growth: "Revenue for Auryxia continues to grow." They say "We continue to expect Auryxia to deliver annual revenue growth for 2021." That's a current expectation, not necessarily a prior one they are confirming. They mention "we are encouraged with how the market views Auryxia’s strengths" but no specific prior expectation. They talk about vadadustat launch preparation. They say "we are deep in commercial preparedness activities" and "we are investing in pre-commercialization activities." But they haven't launched yet. They are preparing for a potential approval. They mention "if vadadustat is approved" and "subject to approval." So it's not yet a real current-period activity in terms of sales. They mention "we have two API and two drug product suppliers for launch" and "we are very comfortable that we'll have adequate supply available at launch." That's preparation, not actual sales. They mention "we anticipate will take approximately six months from regulatory approval to official TDAPA designation" - that's future. They mention "we plan to launch in dialysis as soon as possible after regulatory approval." So no actual launch yet.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| MDLZ | Mondelez International, Inc. | Q4 2016 | 2017-02-07 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| F | Ford Motor Company | Q3 2016 | 2016-10-27 | B+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| TRV | The Travelers Companies, Inc. | Q2 2016 | 2016-07-21 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
ICFI · Q1 2017 → YESThe question is: Does management point to a growth-bearing development that they previously told investors to expect, and now it's arriving with current activity, but still early with most contributio...YES Management explicitly references the themes from their February 2017 full-year earnings call (only two months prior), noting that the January-February pickup they had highlighted there continued through March. They then point to concrete current-period activity: ICF Olson won over $75 million in new revenue since acquisition (neither firm could have won independently), added substantial new-account wins in Q1, and saw its qualified pipeline rise significantly above year-end 2016 levels. John Wasson confirms the new projects and retainers are now lining up, with strong Q1 wins and momentum from added staff. Sudhakar states they expect mid-single-digit growth this 2017 and sequential improvement, while reiterating confidence in the medium-term outlook. The language makes clear the ramp is still early—H2 comparisons and most of the contribution lie ahead—matching the three-part pattern for this growth-bearing development. No other item in the call satisfies all three criteria as cleanly.
HOLX · Q4 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES The transcript shows a clear three-part pattern for international growth. Management explicitly references its prior expectation: “while we thought that international would be a double-digit grower by 2018, we've actually delivered on that promise a year earlier than anticipated.” In the just-reported Q4, they confirm the development with concrete activity 17.5% international growth (excluding Cynosure and blood), the sixth consecutive quarter of double-digit growth for molecular internationally, and Panther shipments exceeding prior-year levels. They also state it is still early with most contribution ahead: “we've actually delivered on that promise a year earlier,” and they hope investors remember this 2017 success story as they evaluate Cynosure 2.
PTC · Q3 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES Management explicitly references its prior long-term growth ambition for IoT (30-40% bookings growth, consistent with the faster-growing IoT market) as part of its double-digit overall plan, which it had communicated as the target to achieve sustainable growth. In the current quarter, it confirms this is materializing with 40%+ of IoT bookings from customer expansions, six-figure deals growing sequentially and year-over-year, and specific closed expansions with leading food/beverage, aerospace/defense, and medical device companies, plus strong contribution from these. It further conveys the development remains early by noting customers are "generally still in the early days of their IoT journeys" with "adoption is gaining momentum" and "further stages" (e.g.